SiriusPoint Finally Closes the Book on Its Past — Now Comes the Hard Part

The reinsurer-turned-specialty-underwriter offloads its legacy runoff, recasts reporting around A&H, and resumes buybacks. The re-rating case is now purely about execution.

SPNT · Earnings Call · 2026-11-06

The last legacy problem gets solved

SiriusPoint spent three years telling investors it was no longer a Bermuda reinsurer. On Nov. 6 it finally bought the proof. The Q3 call was dominated by a loss portfolio transfer with Riverstone covering the remaining runoff book, a segment recast that puts accident & health on its own, and a resumption of buybacks. For a stock up 128% over 43 weeks and sitting 4% below its July peak, the question is no longer whether the turnaround is real. It is whether the clean core is worth materially more than 5.5x earnings.

Put simply, this transaction allows us to effectively close the chapter on the legacy book once and for all.
Scott Egan ACMA, Chief Executive Officer · 2026-11-06

The LPT transaction is the culmination of a cleanup that has been telegraphed for years. The economics are straightforward: “The expected day 1 cost of the LPT is approximately $60 million.” — James J. McKinney, Chief Financial Officer · 2026-11-06 Against that, SiriusPoint frees more than $200 million of capital tied to legacy reserves and lifts its BSCR ratio by roughly 20 points on a pro-forma basis. “We estimate that the LPT will increase the BSCR ratio by approximately 20 points on a pro-forma basis upon close.” — James J. McKinney, Chief Financial Officer · 2026-11-06 The trade only works if the reserves were adequate, which is where the 22 consecutive quarters of favorable development matter. The company is effectively paying Riverstone to take the tail risk it has been carrying since before the 2023 underwriting pivot.

But “close the chapter” is not the same as “close the book.” SiriusPoint retains claims administration, and that carries a real cost. Analyst Michael Phillips pinned management down on the expense line: roughly $15–16 million a year, with a tail of about three years. “it basically has about a 3-year, 2.5- to 3-year, tail with it” — James J. McKinney, Chief Financial Officer · 2026-11-06 Jim McKinney said. So the LPT removes reserve volatility and frees capital, but it does not make the runoff disappear overnight. The runoff reserves are now someone else’s problem; the administrative plumbing is still SiriusPoint’s. That nuance matters because the bull case depends on the market treating the core as clean.

The recast is the real ask

The more consequential announcement may be the segment change. Beginning in Q4, accident & health becomes a standalone segment — a business rating over $1 billion of premium — while the remaining 9 specialties are bundled into a new Specialty P&C segment. “Accident and health, our largest specialty line rating over $1 billion of premium, becomes a standalone segment.” — Scott Egan ACMA, Chief Executive Officer · 2026-11-06 The logic is explicitly about comparability: SiriusPoint wants to be valued alongside US specialty insurers, not Bermuda reinsurers. Management has been making that argument for years; now it is changing the reporting to force the issue.

A&H is the right horse to lead with. It is the largest line at 26% of premium mix, it has a long track record of profitability, and it is relatively low capital intensity. In prior calls, Scott Egan called A&H the portfolio’s “volatility shock-absorber” — Scott Egan, Chief Executive Officer · 2025-08-05 — the business that lets SiriusPoint take more risk elsewhere while keeping overall volatility low. That framing still holds. The new twist is that A&H will now be visible on its own, which should make the quality of the core easier to underwrite for generalist investors.

The timing is deliberate. SiriusPoint still trades at 0.9x revenue and 5.5x net income, multiples that scream “reinsurer with issues” rather than “specialty underwriter.” The stock has re-rated hard — up 128% over 43 weeks — but the valuation gap is still wide versus where a clean specialty insurer might trade. The recast is management’s attempt to close that gap without waiting for the market to figure it out on its own.

The quarter behind the story

The underlying Q3 was solid, not spectacular. Core gross written premium rose 14% to $991 million; insurance and services grew 20%, while reinsurance was deliberately shrunk. The core combined ratio was 90.1%, operating ROE was 17.6%, and core operating ROE — which excludes the runoff — was 18.1%. Year to date, core operating ROE is 17%, above the 12–15% target. $744 million of total revenue was down 1% year over year, a reminder that the top line is being reshaped, not maximized.

The mix is the message. Employer stop loss is showing signs of firming, with rate expectations in excess of 20% in US medical excess of loss. Aviation is getting double-digit rate increases for major airlines. Credit and surety are growing. At the same time, D&O and professional liability remain competitive, auto casualty is being cut, and property cat is down to roughly 4% of the portfolio. This is active portfolio management, not a growth-at-all-costs story. Egan has been consistent on that: “if we don’t see price sort of match the risk that we’re taking, and we’re not frightened to move capital around the group” — Scott Egan, Chief Executive Officer · 2026-05-08.

The capital return piece is smaller than the LPT headline. SiriusPoint bought back $27 million of stock in Q3 but slowed because it was in possession of material nonpublic information around the LPT. It now plans to resume, with $74 million left on the authorization. “Following $27 million of common share repurchases in the quarter, $74 million remains under our authorization.” — James J. McKinney, Chief Financial Officer · 2026-11-06 That is not a huge number against a $3 billion market cap, and the real capital return decision is deferred to the Q4 call after the 2027 planning process. Prior calls set the expectation that buybacks would be opportunistic and potentially front-loaded; “we’ll be opportunistic. And if that means it’s more front-loaded than back loaded, then we are very happy to take that.” — Scott Egan, CEO · 2026-02-19 The LPT frees the capital to do more, but management has not yet committed to a larger program.

What the tape is saying

The stock is not cheap because the market is asleep. It is cheap because the market has been waiting for exactly this — proof that the legacy book is contained and the core is a real specialty franchise. The shares are within 4% of their July high and up 169% over 168 weeks, so a lot of the turnaround is already in the price. The LPT is the last big lever. If the recast works and SiriusPoint gets a specialty insurer multiple, there is still upside; if the market decides the easy money has been made, the next catalyst is the Q4 capital return update.

The broader insurance tape this week was full of companies talking about rate, loss trends, and favorable development — AFG, AIG, KINS and others. SiriusPoint’s Favorable development is not unique; it is a sector-wide theme. What is unique is the LPT and the explicit attempt to rebrand as a specialty insurer. That is the company-specific signal. The balance sheet is strong: liabilities are 82% of assets, debt to capital is 23%, and the BSCR is 232%. The LPT makes it stronger still.

The story from here is simple to state and hard to execute: SiriusPoint has closed the past, recast the present, and now needs the market to pay for the future. The LPT is the cleanest evidence yet that management believes the core is durable. The next 12 months will determine whether the market agrees — or whether SiriusPoint remains a specialty insurer trapped in a reinsurer’s multiple.